Core Viewpoint - Tianyuan Medical (00557) reported a significant decline in revenue and a reduced loss for the six months ending June 30, 2025, indicating ongoing financial challenges but some improvements in loss management [1] Financial Performance - The company achieved a revenue of HKD 8.436 million, representing a year-on-year decrease of 43.23% [1] - The loss attributable to equity holders was HKD 3.065 million, which is a reduction of 45.33% compared to the previous year [1] - The loss per share was HKD 0.77 [1] Loss Management - The reduction in loss was primarily due to a decrease in realized and unrealized valuation losses on securities by approximately HKD 600,000 [1] - The company reversed expected credit losses of about HKD 2.5 million during the period [1] - There was a significant turnaround in foreign exchange losses, with a previous loss of approximately HKD 1.9 million turning into a gain of about HKD 2.7 million [1] - Total revenue decline was offset by a reduction of approximately HKD 6.4 million [1]
天元医疗发布中期业绩，股东应占亏损306.5万港元 同比减少45.33%